{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:49:20Z","timestamp":1788306560095,"version":"build-2803163510"},"reference-count":11,"publisher":"Australian Centre for Disease Control","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Commun Dis Intell"],"abstract":"<jats:p>Invasive meningococcal disease (IMD) is a notifiable disease in Australia, and both probable and laboratory-confirmed cases of IMD are reported to the National Notifiable Diseases Surveillance System (NNDSS). In 2018, there were 281 IMD cases notified to the NNDSS. Of these, 278 were laboratory-confirmed cases analysed by the reference laboratories of the Australian National Neisseria Network (NNN). On investigation, the serogroup was able to be determined for 98.6% (274\/278) of laboratory-confirmed cases. Serogroup B infections accounted for 44.2% of cases (123 cases); serogroup W for 36.3% of cases (101 cases); serogroup Y infections for 15.8% (44 cases) and serogroup C 1.4% (4 cases); and there were two unrelated cases (0.7%) of IMD attributable to serogroup E. Using molecular methods, 181\/278 IMD cases were able to be typed. Of note was that 89% of typed serogroup W IMD cases (66\/74) were porA antigen type P1.5,2; of this number, 44% (29\/66) were sequence type 11, the hypervirulent strain reported in recent outbreaks in Australia and overseas. \nThe primary age peak of IMD in Australia in 2018 was again observed in adults aged 45 years or more; a secondary disease peak was observed in children and infants aged less than 5 years. Serogroup B infections predominated in those aged less than 5 years, whereas serogroup W and serogroup Y infections predominated in those aged 45 years or more. Of the IMD isolates tested for antimicrobial susceptibility, 1.4% (3\/210) were resistant to penicillin with an MIC \u2265 1 mg\/L, and decreased susceptibility to penicillin was observed in a further 93.8% (197\/210) of isolates. All isolates were susceptible to ceftriaxone and rifampicin; there was one isolate less susceptible to ciprofloxacin.<\/jats:p>","DOI":"10.33321\/cdi.2020.44.10","type":"journal-article","created":{"date-parts":[[2020,3,15]],"date-time":"2020-03-15T20:00:26Z","timestamp":1584302426000},"source":"Crossref","is-referenced-by-count":9,"title":["Australian Meningococcal Surveillance Programme annual report, 2018"],"prefix":"10.33321","volume":"44","author":[{"given":"Monica M","family":"Lahra","sequence":"first","affiliation":[{"name":"Neisseria Reference Laboratory and World Health Organisation Collaborating Centre for STI and AMR, Sydney. Department of Microbiology, New South Wales Health Pathology, The Prince of Wales Hospital, Randwick, 2031, NSW Australia; School of Medical Sciences, Faculty of Medicine, The University of New South Wales, NSW, 2052 Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Enriquez","sequence":"additional","affiliation":[{"name":"Neisseria Reference Laboratory and World Health Organisation Collaborating Centre for STI and AMR, Sydney. Department of Microbiology, New South Wales Health Pathology, The Prince of Wales Hospital, Randwick, 2031, NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Hogan","sequence":"additional","affiliation":[{"name":"Neisseria Reference Laboratory and World Health Organisation Collaborating Centre for STI and AMR, Sydney. Department of Microbiology, New South Wales Health Pathology, The Prince of Wales Hospital, Randwick, 2031, NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the National Neisseria Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18788","published-online":{"date-parts":[[2020,3,16]]},"reference":[{"key":"ref0","unstructured":"National Neisseria Network. Meningococcal isolate surveillance Australia 1994. Commun Dis Intell. 1995;19(12)286\u20139."},{"key":"ref1","unstructured":"Australian Government Department of Health. National Notifiable Disease Surveillance System (NNDSS). [Internet.] Australian Government Department of Heath, 2019. Available from: http:\/\/www9.health.gov.au\/cda\/source\/cda-index.cfm ."},{"key":"ref2","unstructured":"NNDSS. Number of notifications of Meningococcal disease (invasive), received from state and territory health authorities in the period of 1991 to 2012 and year-to-date notifications for 2014. [Internet.] Australian Government Department of Health, NNDSS, 2014."},{"key":"ref3","unstructured":"Australian Government Department of Health. Meningococcal Disease (Invasive). [Internet.] Australian Government Department of Health, 2019. Available from: https:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/ohp-meningococcal-W.htm ."},{"key":"ref4","unstructured":"Communicable Diseases Network Australia. Invasive Meningococcal Disease: CDNA National Guidelines for Public Health Units. [Internet.] Australian Government Department of Health, 2017. Available from: http:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/content\/cdna-song-imd.htm."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Abad R, L\u00f3pez EL, Debbag R, V\u00e1zquez JA. Serogroup W meningococcal disease: global spread and current affect on the Southern Cone in Latin America. Epidemiol Infect. 2014;142(12):2461\u201370.","DOI":"10.1017\/s0950268814001149"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Ladhani SN, Beebeejaun K, Lucidarme J, Campbell H, Gray S, Kaczmarski E, et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis. 2015;60(4):578\u201385.","DOI":"10.1093\/cid\/ciu881"},{"key":"ref7","unstructured":"Chiu C, Dey A, Wang H, Menzies R, Deeks S, Mahajan D et al. Vaccine preventable diseases in Australia, 2005 to 2007. Commun Dis Intell Q Rep. 2010;34:S1\u2013167."},{"key":"ref8","unstructured":"Australian Government Department of Health. Meningococcal Disease. Immunise Australia Program. [Internet.] Australian Government Department of Heath, 2015. Available from: http:\/\/www.health.gov.au\/internet\/immunise\/publishing.nsf\/Content\/immunise-meningococcal"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Araya P, Fern\u00e1ndez J, Del Canto F, Seoane M, Ibarz-Pav\u00f3n AB, Barra G, Pidal P et al. Neisseria meningitidis ST-11 clonal complex, Chile 2012. Emerg Infect Dis. 2015;21(2):339\u201341.","DOI":"10.3201\/eid2102.140746"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Br\u00f6ker M, Jacobsson S, Kuusi M, Pace D, Sim\u00f5es MJ, Skoczynska A et al. Meningococcal serogroup Y emergence in Europe: update 2011. Hum Vaccin Immunother. 2012;8(12):1907\u201311.","DOI":"10.4161\/hv.21794"}],"container-title":["Communicable Diseases Intelligence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www1.health.gov.au\/internet\/main\/publishing.nsf\/Content\/8FA6078276359430CA257BF0001A4C42\/$File\/australian_meningococcal_surveillance_programme_annual_report_2018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T18:39:34Z","timestamp":1749580774000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojs.cdi.cdc.gov.au\/index.php\/cdi\/article\/view\/213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,16]]},"references-count":11,"URL":"https:\/\/doi.org\/10.33321\/cdi.2020.44.10","archive":["Portico","Portico"],"relation":{},"ISSN":["2209-6051"],"issn-type":[{"value":"2209-6051","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,16]]}}}